TY - JOUR
T1 - DCFPyL PET/CT for Imaging of Prostate Cancer
AU - Rowe, Steven P.
AU - Buck, Andreas
AU - Bundschuh, Ralph A.
AU - Lapa, Constantin
AU - Serfling, Sebastian E.
AU - Derlin, Thorsten
AU - Higuchi, Takahiro
AU - Gorin, Michael A.
AU - Pomper, Martin G.
AU - Werner, Rudolf A.
N1 - Funding Information:
Under a license agreement between Progenics (a wholly-owned subsidiary of Lantheus) and the Johns Hopkins University, MGP and the University are entitled to royalties on an invention described in this article. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. SPR is a consultant for Progenics Pharmaceuticals, Inc. MAG has been a consultant for Progenics Pharmaceuticals, Inc. This work was supported by the “RECTOR” Program at Okayama (TH). All other authors declare that there is no conflict of interest as well as consent for scientific analysis and publication.
Publisher Copyright:
© 2022 Georg Thieme Verlag. All rights reserved.
PY - 2022/6/3
Y1 - 2022/6/3
N2 - Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, 68Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of 18F-labeled agents. Among others, [ 18F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [ 18F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this 18F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [ 18F]DCFPyL in various clinical settings for men with PC.
AB - Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, 68Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of 18F-labeled agents. Among others, [ 18F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [ 18F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this 18F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [ 18F]DCFPyL in various clinical settings for men with PC.
KW - F-DCFPyL
KW - Prostate Cancer
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85129371464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129371464&partnerID=8YFLogxK
U2 - 10.1055/a-1659-0010
DO - 10.1055/a-1659-0010
M3 - Review article
C2 - 35030637
AN - SCOPUS:85129371464
SN - 0029-5566
VL - 61
SP - 240
EP - 246
JO - Nuklearmedizin - NuclearMedicine
JF - Nuklearmedizin - NuclearMedicine
IS - 3
ER -
